Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Phase 2
Conditions
Lung Cancer
First Posted Date
2004-05-17
Last Posted Date
2011-03-01
Lead Sponsor
American College of Radiology Imaging Network
Target Recruit Count
250
Registration Number
NCT00083083
Locations
🇺🇸

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States

🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

🇺🇸

West Michigan Cancer Center, Kalamazoo, Michigan, United States

and more 46 locations

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Phase 3
Completed
Conditions
Neuroblastoma
First Posted Date
2004-05-12
Last Posted Date
2013-12-19
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
500
Registration Number
NCT00002802
Locations
🇩🇪

University of Cologne, Frechen, Germany

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors

First Posted Date
2004-05-04
Last Posted Date
2016-01-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
25
Registration Number
NCT00008125
Locations
🇺🇸

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma

First Posted Date
2004-05-03
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
17
Registration Number
NCT00005021
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.

Phase 2
Completed
Conditions
Carcinoma of Unknown Primary
Lung Cancer
First Posted Date
2004-05-03
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
3
Registration Number
NCT00003943
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Johns Hopkins Oncology Center, Baltimore, Maryland, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2004-05-03
Last Posted Date
2010-04-02
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
280
Registration Number
NCT00003972
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Phase 1
Terminated
Conditions
Ovarian Cancer
First Posted Date
2004-05-03
Last Posted Date
2012-09-26
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
3
Registration Number
NCT00005612
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
First Posted Date
2004-04-30
Last Posted Date
2013-06-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
18
Registration Number
NCT00003394
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 3
Conditions
Lung Cancer
First Posted Date
2004-04-26
Last Posted Date
2013-12-19
Lead Sponsor
AstraZeneca
Registration Number
NCT00006049
Locations
🇺🇸

AstraZeneca Pharmaceuticals LP, Wilmington, Delaware, United States

Carboplatin Plus Vincristine in Treating Children With Retinoblastoma

Phase 2
Completed
Conditions
Retinoblastoma
First Posted Date
2004-04-26
Last Posted Date
2011-10-04
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
25
Registration Number
NCT00002794
Locations
🇺🇸

Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy